SANA BIOTECHNOLOGY INC. - COMMON STOCK

Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day Conference

30 9 2024 16:05:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology to Present at September 2024 Investor Conferences

29 8 2024 16:05:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer

26 8 2024 16:05:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology Reports Second Quarter 2024 Financial Results and Business Updates

08 8 2024 16:05:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington’s Disease and Other Glial-based Neurodegenerative Conditions

21 5 2024 09:00:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates

08 5 2024 16:05:01 提供 Nasdaq GlobeNewswire

Sana Biotechnology to Present at May and June 2024 Investor Conferences

06 5 2024 16:05:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

29 2 2024 16:05:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference

28 2 2024 16:05:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP

13 2 2024 16:05:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

12 2 2024 16:05:48 提供 Nasdaq GlobeNewswire

Sana Biotechnology Announces Pricing of Upsized Public Offering

08 2 2024 01:22:20 提供 Nasdaq GlobeNewswire

Sana Biotechnology Announces Proposed Public Offering of Common Stock

07 2 2024 16:01:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies

05 1 2024 09:00:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 1 2024 16:05:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting

11 12 2023 09:00:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune System

01 12 2023 16:05:35 提供 Nasdaq GlobeNewswire

Sana Biotechnology to Present at November and December 2023 Investor Conferences

21 11 2023 09:00:00 提供 Nasdaq GlobeNewswire

Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes

17 11 2023 09:00:00 提供 Nasdaq GlobeNewswire

Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis

09 11 2023 16:05:00 提供 Nasdaq GlobeNewswire